These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3281595)

  • 41. Excess granulation tissue during etretinate therapy.
    Hodak E; David M; Feuerman EJ
    J Am Acad Dermatol; 1984 Dec; 11(6):1166-7. PubMed ID: 6512060
    [No Abstract]   [Full Text] [Related]  

  • 42. A study of potential hepatotoxicity of etretinate used in the treatment of psoriasis.
    Glazer SD; Roenigk HH; Yokoo H; Sparberg M
    J Am Acad Dermatol; 1982 Apr; 6(4 Pt 2 Suppl):683-7. PubMed ID: 7068976
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of psoriatic rheumatism with a retinoid derivative: etretinate. Open preliminary trial on 12 patients reviewed after 6 months].
    Rampon S; Fraysse MP; Ristori JM; Sauvezie B; Bussière JL; Souteyrand P
    Rev Rhum Mal Osteoartic; 1985 Feb; 52(2):127-31. PubMed ID: 3872473
    [No Abstract]   [Full Text] [Related]  

  • 44. Etretinate therapy causes increases in lipid levels in patients with psoriasis.
    Ellis CN; Swanson NA; Grekin RC; Goldstein NG; Bassett DR; Anderson TF; Voorhees JJ
    Arch Dermatol; 1982 Aug; 118(8):559-62. PubMed ID: 7103524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short clinical reports: serum lipid changes during etretinate therapy.
    J Am Acad Dermatol; 1982 Apr; 6(4 Pt 2 Suppl):732-4. PubMed ID: 7068979
    [No Abstract]   [Full Text] [Related]  

  • 46. A three-year follow-up study of psoriasis patients treated with low dosages of etretinate orally and corticosteroids topically.
    Polano MK; van der Rhee HJ; van der Schroeff JG
    Acta Derm Venereol; 1982; 62(4):361-4. PubMed ID: 6183880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis.
    Lawrence CM; Marks J; Parker S; Shuster S
    Br J Dermatol; 1984 Feb; 110(2):221-6. PubMed ID: 6696838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Etretinate (Tigason) for skin disease.
    Drug Ther Bull; 1983 Feb; 21(3):9-11. PubMed ID: 6839967
    [No Abstract]   [Full Text] [Related]  

  • 49. [Psoriasis therapy with the aromatic retinoid Ro 10-9359 (Tigason)].
    Sönnichsen N; Harnack K; Barth J; Heilmann S; Jäger K; Metz D; Schiller F
    Z Hautkr; 1983 Sep; 58(17):1257-67. PubMed ID: 6636927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sarcoid-like granuloma following prolonged etretinate treatment.
    Fernández-Redondo V; Vázquez J; Sánchez-Aguilar D; Toribio J
    Dermatology; 1994; 188(3):226-7. PubMed ID: 8186514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of etretinate (Tigason) and parenteral gold in the treatment of psoriatic arthropathy.
    Seppälä J; Laulainen M; Reunala T
    Clin Rheumatol; 1988 Dec; 7(4):498-503. PubMed ID: 3149925
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Depression induced by etretinate.
    Henderson CA; Highet AS
    BMJ; 1989 Apr; 298(6678):964. PubMed ID: 2497882
    [No Abstract]   [Full Text] [Related]  

  • 53. [Vertebral hyperostosis induced by etretinate].
    Hans P; Pompougnac E; Barucq JP; Barucq P; Beylot C
    Rev Rhum Mal Osteoartic; 1988 Dec; 55(12):1027-9. PubMed ID: 3238301
    [No Abstract]   [Full Text] [Related]  

  • 54. Methotrexate and etretinate as concurrent therapies in severe psoriasis.
    Vanderveen EE; Ellis CN; Campbell JP; Case PC; Voorhees JJ
    Arch Dermatol; 1982 Sep; 118(9):660-2. PubMed ID: 7114868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The retinoids, Part II.
    Long K; Long R
    Nurse Pract Forum; 1995 Jun; 6(2):60-1. PubMed ID: 7620395
    [No Abstract]   [Full Text] [Related]  

  • 56. American Academy of Pediatrics Committee on Drugs: Retinoid therapy for severe dermatological disorders.
    Pediatrics; 1992 Jul; 90(1 Pt 1):119-20. PubMed ID: 1535432
    [No Abstract]   [Full Text] [Related]  

  • 57. [Skeletal changes caused by etretinate].
    Crespi HG; Massimo JA; Gentile F; Cordero AA
    Med Cutan Ibero Lat Am; 1986; 14(2):77-81. PubMed ID: 3528712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports).
    Kokelj F; Plozzer C; Torsello P; Trevisan G
    J Eur Acad Dermatol Venereol; 1998 Sep; 11(2):177-9. PubMed ID: 9784049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pilot study of etretinate in psoriatic arthritis.
    Klinkhoff AV; Gertner E; Chalmers A; Gladman DD; Stewart WD; Schachter GD; Schachter RK
    J Rheumatol; 1989 Jun; 16(6):789-91. PubMed ID: 2778761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Unusual side effects in patients with psoriatic erythroderma treated with etretinate (RO 10-9359)].
    Castel T; Castro J; Lecha M; Mascaró JM
    Med Cutan Ibero Lat Am; 1986; 14(2):83-6. PubMed ID: 2943953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.